December 12, 2016 | Five Year Forward View, Vanguards
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore the opportunities for pharma to help NHS vanguards develop new models of care.
Introduction
Vanguards are individual organisations and partnerships that have been asked to trial new ways of running primary and secondary care services in their local area as part of the NHS’s Five Year Forward View (FYFV).
Vanguards aim to make health services more accessible and more effective for patients by dismantling NHS care pathways that are no longer working well and taking a fresh approach to service design.
Better communication and joined up working between different parts of the NHS, including GP and hospital services, emergency services and community-based organisations, are integral to this new approach.
Earlier this year, NHiS Commissioning Excellence, which is part of Wilmington Healthcare, organised an advisory panel discussion, involving eight vanguards, including four multispecialty community providers, a GP super-practice and an acute care collaboration. Representatives shared their experiences and discussed planned initiatives and objectives.
Our subsequent report entitled ‘The Role of Vanguards in the Development of New NHS Commissioning Structures’, provides fascinating evidence of how NHS vanguards are redefining patient pathways and trialling new ways of working. http://www.nhis.com/vanguard-report-2016
How can pharma get involved with vanguards?
Rather than asking vanguards how it can help, pharma should offer tailored solutions that fill clearly identified needs. For example, if a vanguard is working in a disease area that is relevant to your company, then find out what you can do to help. However, try to be generic in your approach, since many vanguards want to tackle wider issues around diseases. For example, pharma could identify how many people with epilepsy use A&E following a seizure, but the wider vanguard perspective could be to risk stratify why any patients, including those with epilepsy, attend A&E.
Pharma could also identify new issues. For example, NHiS identified a huge number of emergency hospital admissions for urinary tract infections in several NHS Clinical Networks which led to a review of how these are managed in primary care.
All vanguards have been running for at least a year, so they are already quite advanced. Also, they are working to a plan which is very tightly monitored by NHS England: consequently, they aren’t interested in proposals that would require them to deviate from it. What they do want from pharma is something that could help them achieve their goals quicker.
Since technology, such as Skype and decision support software are key to transforming the NHS, this could involve the development of digital tools, phone apps and other IT services like remote diagnostic or review tools. It could also involve partnership working on relevant vanguard programmes. It is vital to keep abreast of what is happening in vanguards and attending key national conferences to listen, rather than to sell, is important.
Conclusion
Vanguards are leading the way in helping to develop new models of care that will become a blueprint for the NHS. The commercial benefits for pharma companies that get involved with vanguards at this early stage could be immense. But the onus is on pharma to decipher where it can plug gaps and to propose joint working initiatives that will help vanguards to achieve their goals.
Sue Thomas is CEO of the Commissioning Excellence Directorate and Paul Midgley is director of NHS insight, both at Wilmington Healthcare. www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...